Trial Profile
With Open, Single/Multiple Dosing and Dose Escalation, Phase I Clinical Trial Scheme to Evaluate Safety, Tolerance and Pharmacokinetic Properties of Genolimzumab Injection
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Mar 2023
Price :
$35
*
At a glance
- Drugs Geptanolimab (Primary)
- Indications B-cell lymphoma; Bladder cancer; Head and neck cancer; Hodgkin's disease; Liver cancer; Lymphoma; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Peripheral T-cell lymphoma; Primitive neuroectodermal tumours; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Acronyms GB226
- Sponsors Genor Biopharma
- 12 Aug 2021 Planned primary completion date changed from 1 Jun 2021 to 1 Jun 2022.
- 02 Mar 2021 Planned End Date changed from 1 Aug 2020 to 1 Aug 2022.
- 02 Mar 2021 Planned primary completion date changed from 1 Jun 2020 to 1 Jun 2021.